Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.5%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (39.1%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.7%), Switzerland (1%), Europe-Middle East-Africa (22.9%), United States (33.1%), North America (3.6%), China (7.6%), Asia-Pacific (8.9%), Brazil (9.6%), and Latin America (7.6%).

Employees

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
15/07/26	€47.93	-2.29%
14/07/26	€49.06	-1.83%
13/07/26	€49.97	-0.38%
10/07/26	€50.16	-0.87%
09/07/26	€50.60	+2.16%

Real-time CBOE EUROPE EQUITIES - EUROPEAN EQUITIES (NL)

More quotes

Analysis / Opinion

Bayer: Inching closer to being unshackled

June 01, 2026 at 01:37 am

Can Bayer Still Recover?

May 21, 2026 at 04:06 pm

Roundup: Bayer ordered to pay $2.1bn to an American suffering from cancer

March 24, 2025 at 06:21 pm

More analyses

Market Closed - CBOE EUROPE EQUITIES - EUROPEAN EQUITIES (NL) Other stock markets 23:30:00 15/07/2026 HKT			After hours 00:52:51
47.93 ^EUR	-2.29%		47.63	-0.63%

04:23pm	Bayer, RAGT Enter Licensing Deal to Launch Hybrid Wheat Seeds	MT
07-15	ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer	MT

Market Cap	48.26B 55.19B 44.52B 40.92B 77.54B 5,311B 78.86B 531B 209B 2,596B 207B 203B 8,947B	P/E 2026 *	21.2x	P/E 2027 *	15.9x
Enterprise Value	80.1B 91.61B 73.89B 67.92B 129B 8,815B 131B 882B 346B 4,309B 344B 337B 14,851B	EV / Sales 2026 *	1.76x	EV / Sales 2027 *	1.65x
Free-Float	100%	Yield 2026 *	0.46%	Yield 2027 *	1.28%

04:23pm	Bayer, RAGT Enter Licensing Deal to Launch Hybrid Wheat Seeds	MT
07-15	ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer	MT
07-14	Where would AI lead Pharma in the long run?
07-14	BAYER AG : Gets a Buy rating from Barclays	ZD
07-14	Fitch Affirms Bayer Rating, Negative Outlook Amid Near-term Uncertainties	MT
07-13	EU member states can cushion fertilizer prices	DP
07-13	BAYER AG : UBS keeps its Buy rating	ZD
07-13	Pesticide makers stack wins against US environmental, public health groups	RE
07-13	BAYER AG : Jefferies sticks Neutral	ZD
07-13	Jefferies keeps Bayer at 'Hold', target €46	DP
07-12	Moody's Upgrades Bayer Outlook With Rating Affirmation on "Positive" Court Decision	MT
07-11	Bayer in the red despite an improved balance sheet structure thanks to Apollo	DP
07-10	European Equities Mixed in Friday Trading; Apollo Enters Bid for EasyJet	MT

07-14	Where would AI lead Pharma in the long run?
07-14	BAYER AG : Gets a Buy rating from Barclays	ZD
07-13	BAYER AG : UBS keeps its Buy rating	ZD
07-13	BAYER AG : Jefferies sticks Neutral	ZD
07-13	Jefferies keeps Bayer at 'Hold', target €46	DP

Bayer AG Stock CBOE EUROPE EQUITIES - EUROPEAN EQUITIES (NL)

Stocks

BAYNd

DE000BAY0017

Pharmaceuticals

Valuation: Bayer AG

Chart: Bayer AG

Latest news : Bayer AG

Last Transcript: Bayer AG

Analysts' recommendations: Bayer AG

Press Releases: Bayer AG

News in other languages: Bayer AG

Quotes and Performance

Course Extremes

Managers and Directors: Bayer AG

Other Pharmaceuticals

Financials

Company Profile

Quotes

Analysis / Opinion

03:34pm	Bayer : signs licensing agreement with RAGT and begins broad hybrid wheat commercialization by early 2030s	PU
07-14	Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farming	BU
07-14	Bayer : Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farming	PU
07-10	Bayer : secures 3.0 billion euros to improve capital structure	PU
07-10	Bayer Aktiengesellschaft: Bayer secures 3.0 billion euros to improve capital structure	EQ

05:25pm	Bayer signe un accord de licence avec le semencier français RAGT
04:53pm	Bayer schließt Lizenzvereinbarung mit französischem Weizensaatguthersteller RAGT
03:34pm	Bayer : schließt Lizenzvereinbarung mit RAGT und bringt Hybridweizen Anfang der 2030er Jahre auf den Markt
07-14	Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
07-14	Autonome Technologien in der Landwirtschaft: Sabanto schließt überzeichnete Serie-B-Finanzierungsrunde mit Leaps by Bayer als führendem Investor ab

1 week	-3.23%
Current month	-0.37%
1 month	+32.62%
3 months	+17.50%
6 months	+14.00%
Current year	+29.56%

1 week	47.53	52.08
1 month	35.67	53.9
3 years	18.39	53.9
5 years	18.39	67.99

Manager	Title	Age	Since
William Anderson CEO	Chief Executive Officer	59	01/06/2023
Judith Hartmann DFI	Director of Finance/CFO	57	01/06/2026
Philipp Blank CMP	Compliance Officer	-	-

Director	Title	Age	Since
André van Broich BRD	Director/Board Member	56	01/04/2012
Heike Hausfeld BRD	Director/Board Member	60	01/04/2017
Norbert Winkeljohann CHM	Chairman	68	28/04/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BAYER AG	-2.29%	+2.48%	+74.67%	-4.73%	55.22B
ELI LILLY AND COMPANY	-0.69%	-6.07%	+47.98%	+155.41%	1,028B
JOHNSON & JOHNSON	-1.04%	-4.65%	+61.86%	+57.89%	611B
ABBVIE INC.	+1.57%	-2.19%	+32.63%	+83.35%	432B
ROCHE HOLDING AG	+0.98%	-1.40%	+29.49%	+23.12%	323B
NOVARTIS AG	-0.34%	-3.10%	+27.00%	+43.66%	277B
ASTRAZENECA PLC	+1.63%	-11.76%	+19.72%	+23.20%	257B
NOVO NORDISK A/S	+3.39%	+2.29%	-23.68%	-38.33%	217B
AMGEN INC.	+0.91%	-2.31%	+22.90%	+57.78%	192B
GILEAD SCIENCES, INC.	+1.91%	-2.23%	+21.76%	+71.39%	161B
Average	+1.01%	-5.24%	+31.43%	+47.27%	388.7B
Weighted average by Cap.	+0.43%	-5.52%	+36.64%	+76.19%

	2026 *	2027 *
Net sales	45.6B 52.16B 42.07B 38.67B 73.27B 5,019B 74.53B 502B 197B 2,453B 196B 192B 8,455B	46.76B 53.48B 43.13B 39.65B 75.13B 5,146B 76.41B 515B 202B 2,515B 201B 196B 8,669B
Net income	2.13B 2.43B 1.96B 1.8B 3.42B 234B 3.47B 23.42B 9.19B 114B 9.13B 8.93B 394B	2.93B 3.35B 2.71B 2.49B 4.71B 323B 4.79B 32.3B 12.67B 158B 12.6B 12.32B 544B
Net Debt	31.84B 36.42B 29.37B 27B 51.16B 3,504B 52.04B 351B 138B 1,713B 137B 134B 5,904B	28.71B 32.84B 26.49B 24.35B 46.13B 3,160B 46.92B 316B 124B 1,545B 123B 121B 5,323B